Current and emerging treatment options for vulvovaginal atrophy

Jill M. Krapf, Zoe Belkin, Frank Dreher, Andrew T. Goldstein

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

Vulvovaginal atrophy in postmenopausal women is common and manifests in vaginal dryness, irritation, itching, dysuria, and dyspareunia. Treatment used to be limited to estrogen-containing regimens which pose safety concerns. Today, however, practitioners are becoming better equipped to offer a wider range of treatment options due to increased reassurance of safety for existing therapies and advances in novel treatment options. Novel options include selective estrogen receptor modulators (SERMs), tissue-selective estrogen complexes (TSECs), local androgens such as testosterone and dehydroepiandrosterone (DHEA), the peptide hormone oxytocin, as well as phytoestrogens such as genistein and daidzein found in soybeans. Nonhormonal, over-the-counter vaginal lubricants and moisturizers are additional treatment options, in particular, for women contraindicated to estrogen use.

Original languageEnglish (US)
Title of host publicationSkin, Mucosa and Menopause
Subtitle of host publicationManagement of Clinical Issues
PublisherSpringer Berlin Heidelberg
Pages229-235
Number of pages7
ISBN (Electronic)9783662440803
ISBN (Print)9783662440797
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Current and emerging treatment options for vulvovaginal atrophy'. Together they form a unique fingerprint.

Cite this